Photocure ASA ( (PHCUF) ) has released its Q2 earnings. Here is a breakdown of the information Photocure ASA presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Photocure ASA, a company specializing in transformative solutions for bladder cancer patients, manufactures and commercializes Hexvix/Cysview, a product used for the detection and treatment of non-muscle invasive bladder cancer. In the second quarter of 2025, Photocure reported an 11% increase in Hexvix/Cysview revenue, reaching an all-time high of NOK 135.6 million. This growth was driven by a 14% increase in North American sales and an 8% increase in European sales, despite a decline in flexible cystoscopy kit sales. The company’s EBITDA for the commercial segment rose to NOK 24.4 million, up from NOK 11.8 million in the same period last year. Photocure continues to expand its blue light cystoscopy use with new installations in the U.S. and Europe, enhancing its market presence. Looking ahead, Photocure expects product revenue growth between 7% and 11% for 2025, with continued improvements in EBITDA, driven by strategic expansions and partnerships.